The U.S. Food and Drug Administration (FDA) has announced that more than 580,000 bottles of a blood pressure medication are being recalled due to potential contamination with a cancer-causing chemical. The voluntary nationwide recall was initiated by New Jersey-based Teva Pharmaceuticals USA in collaboration with drug distributor Amerisource Health Services.
The medication in question, prazosin hydrochloride, is available in various strengths, specifically 1 mg, 2 mg, and 5 mg capsules. Prazosin is typically used to relax blood vessels, thereby enhancing blood flow, and is also sometimes prescribed for treating nightmares and sleep disturbances associated with post-traumatic stress disorder (PTSD).
In the recall notices released on its website, the FDA has classified the affected lots of prazosin as a Class II risk. This classification indicates that the medication may contain nitrosamine impurities, which are regarded as potentially carcinogenic. Such impurities can occur during the manufacturing or storage processes of the drug.
As of now, Teva Pharmaceuticals has not released any comments regarding the recall. It is essential for consumers who may have these medications to consult with healthcare professionals to assess their risks and consider alternatives if needed.
The FDA continues to monitor the situation closely and urges the public to report any adverse effects associated with the use of the recalled medication. This proactive measure underscores the commitment of regulatory bodies to ensure the safety and well-being of patients across the nation.